Interestingly, advanced forms of MM expressed high levels of MYC and ETC subunits, and were suppressed by tigecycline in vitro and in vivo [300], pointing to mitochondrial inhibition as a possible strategy to overcome therapy resistance in MM. The gene discussed is MYC; the disease is Miyoshi myopathy.